vs
Side-by-side financial comparison of AVAX ONE TECHNOLOGY LTD. (AVX) and PLUS THERAPEUTICS, INC. (PSTV). Click either name above to swap in a different company.
PLUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.4M vs $1.0M, roughly 1.3× AVAX ONE TECHNOLOGY LTD.). PLUS THERAPEUTICS, INC. runs the higher net margin — -417.9% vs -1633.6%, a 1215.6% gap on every dollar of revenue.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
AVX vs PSTV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.4M |
| Net Profit | $-16.6M | $-5.7M |
| Gross Margin | — | — |
| Operating Margin | -1522.1% | -420.0% |
| Net Margin | -1633.6% | -417.9% |
| Revenue YoY | — | -3.2% |
| Net Profit YoY | -480.2% | -46.4% |
| EPS (diluted) | $32.17 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $1.4M | ||
| Q3 25 | $525.9K | $1.4M | ||
| Q2 25 | $452.0K | $1.4M | ||
| Q1 25 | $344.4K | $1.1M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | $0 | $1.5M | ||
| Q2 24 | $41.3K | $1.3M | ||
| Q1 24 | — | $1.7M |
| Q4 25 | $-16.6M | $-5.7M | ||
| Q3 25 | $-8.4M | $-4.4M | ||
| Q2 25 | $-8.1M | $5.2M | ||
| Q1 25 | $-145.5K | $-17.4M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | $-5.8M | $-2.9M | ||
| Q2 24 | $-4.2M | $-2.9M | ||
| Q1 24 | — | $-3.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 22.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 18.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | -1522.1% | -420.0% | ||
| Q3 25 | -496.6% | -320.8% | ||
| Q2 25 | -328.4% | -110.6% | ||
| Q1 25 | -600.0% | -333.9% | ||
| Q4 24 | — | -276.2% | ||
| Q3 24 | — | -260.9% | ||
| Q2 24 | -2827.7% | -289.1% | ||
| Q1 24 | — | -196.7% |
| Q4 25 | -1633.6% | -417.9% | ||
| Q3 25 | -1588.0% | -316.6% | ||
| Q2 25 | -1783.4% | 370.6% | ||
| Q1 25 | -42.2% | -1643.2% | ||
| Q4 24 | — | -276.4% | ||
| Q3 24 | — | -197.4% | ||
| Q2 24 | -10243.5% | -229.9% | ||
| Q1 24 | — | -194.5% |
| Q4 25 | $32.17 | $0.95 | ||
| Q3 25 | $-5.55 | $-0.04 | ||
| Q2 25 | $-27.60 | $-0.01 | ||
| Q1 25 | $-1.17 | $-1.19 | ||
| Q4 24 | — | $-0.51 | ||
| Q3 24 | $-57.19 | $-0.37 | ||
| Q2 24 | $-83.03 | $-0.71 | ||
| Q1 24 | — | $-0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $187.0M | $4.0M |
| Total Assets | $195.0M | $16.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $8.6M | ||
| Q3 25 | $894.7K | $16.6M | ||
| Q2 25 | $185.3K | $6.9M | ||
| Q1 25 | $1.4M | $9.9M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.8M | ||
| Q2 24 | — | $8.4M | ||
| Q1 24 | — | $3.2M |
| Q4 25 | — | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $187.0M | $4.0M | ||
| Q3 25 | $12.2M | $5.1M | ||
| Q2 25 | $4.1M | $3.0M | ||
| Q1 25 | $6.4M | $-23.6M | ||
| Q4 24 | — | $-8.9M | ||
| Q3 24 | $6.7M | $-5.2M | ||
| Q2 24 | $11.3M | $-7.6M | ||
| Q1 24 | — | $-4.8M |
| Q4 25 | $195.0M | $16.3M | ||
| Q3 25 | $16.5M | $18.7M | ||
| Q2 25 | $15.2M | $10.3M | ||
| Q1 25 | $16.8M | $12.1M | ||
| Q4 24 | — | $6.6M | ||
| Q3 24 | $10.8M | $7.0M | ||
| Q2 24 | $15.7M | $11.2M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | — | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-6.3M |
| Free Cash FlowOCF − Capex | — | $-6.3M |
| FCF MarginFCF / Revenue | — | -459.9% |
| Capex IntensityCapex / Revenue | — | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | $-6.3M | ||
| Q3 25 | $-2.4M | $-2.5M | ||
| Q2 25 | $-884.1K | $-5.8M | ||
| Q1 25 | $-2.2M | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | $-1.2M | $-3.7M | ||
| Q2 24 | $-919.2K | $-1.1M | ||
| Q1 24 | — | $-4.5M |
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-1.2M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | — | -459.9% | ||
| Q3 25 | — | -184.3% | ||
| Q2 25 | — | -417.6% | ||
| Q1 25 | — | -583.1% | ||
| Q4 24 | — | -86.5% | ||
| Q3 24 | — | -253.7% | ||
| Q2 24 | — | -96.2% | ||
| Q1 24 | — | -271.5% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.13× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
